Takotsubo syndrome therapeutics sales will grow through 2036, led by echocardiography at 45.6% of the diagnosis segment in 2026. The market was valued at USD 3.3 billion in 2025 and is expected to be worth USD 6.6 billion by 2036, creating an incremental opportunity of USD 3.09 billion.